Mainz Biomed B.V. Stock (NASDAQ:MYNZ)

Revenue Ownership Financials Chart

Previous Close

$0.32

52W Range

$0.28 - $3.75

50D Avg

$0.37

200D Avg

$0.78

Market Cap

$6.67M

Avg Vol (3M)

$1.46M

Beta

0.12

Div Yield

-

MYNZ Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

DE

Employees

65

IPO Date

Nov 05, 2021

Website

MYNZ Performance

MYNZ Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$895.48K	$529.88K	$577.35K
Operating Income	$-26.64M	$-26.17M	$-9.38M
Net Income	$-26.30M	$-26.45M	$-12.07M
EBITDA	$-24.67M	$-25.65M	$-9.27M
Basic EPS	$-1.62	$-1.87	$-1.67
Diluted EPS	$-1.62	$-1.87	$-1.67

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
GTH	Genetron Holdings Limited
APDN	Applied DNA Sciences, Inc.
LAB	Standard BioTools Inc.
LMDX	LumiraDx Limited
SERA	Sera Prognostics, Inc.
BNR	Burning Rock Biotech Limited
PRE	Prenetics Global Limited
NOTV	Inotiv, Inc.
DRIO	DarioHealth Corp.
NDRA	ENDRA Life Sciences Inc.
OLK	Olink Holding AB (publ)
BDSX	Biodesix, Inc.
FONR	FONAR Corporation
STIM	Neuronetics, Inc.
MDXH	MDxHealth SA